Brainstorm Cell Therapeutics Announces Nasdaq Delisting And Transition To Otcqb
ReutersJul 17, 2025 10:24 PM
Brainstorm Cell Therapeutics Inc BCLI.O:
BRAINSTORM CELL THERAPEUTICS ANNOUNCES NASDAQ DELISTING AND TRANSITION TO OTCQB
BRAINSTORM CELL THERAPEUTICS INC - STOCK TO BE SUSPENDED ON NASDAQ AT OPEN OF TRADING ON JULY 18, 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
NEM 2Q25 Earnings Preview
TradingKey - Newmont Corp. will release its earnings for the second quarter of the fiscal 2025 on July 24th after the bell. 2Q25 Earnings per share: $1.15 estimate vs. 2Q24 actual of $0.72 (+60% y/y).2Q25 Revenue: $4.83bn estimate vs. 2Q24 actual of $4.40bn (+10% y/y)TradingKey
2 hours ago
.jpg)
Best Buy: From Retail to Digital Health: Can Diversification Deliver Surprises?
TradingKey - Best Buy, a leader in consumer electronics retail, boasts a strong brand and extensive store network. Despite tariff and competitive pressures, its diversified revenue and new strategic initiatives like Best Buy Marketplace, advertising, and health tech investments are expected to driveTradingKey
4 hours ago
.jpg)
Swiss Franc: Range Trading as the Optimal Investment Strategy
TradingKey - The Swiss Franc faces counteracting bullish and bearish pressures. Given these dynamics, the USD/CHF pair is likely to trade within a range in the near term. In terms of investment strategy, investors should closely monitor the 0.78 low and 0.84 high of this currency pair.TradingKey
4 hours ago
Tradingkey
